Department of Neurosurgery, Cerebrovascular Center, Stony Brook University Medical Center, Stony Brook, New York, USA.
World Neurosurg. 2011 Dec;76(6 Suppl):S66-70. doi: 10.1016/j.wneu.2011.07.024.
The Gateway balloon-Wingspan stent system is the first, and currently the only "on-label" device for the treatment of symptomatic intracranial stenosis in the United States. In initial single-arm studies, investigators have indicated that this system can be used for the treatment of symptomatic intracranial atherosclerotic disease with high levels of technical success and acceptable periprocedural complication rates, which are comparable with, or better than, those reported for other endovascular techniques. Intermediate- and long-term follow-up data for patients treated with the Wingspan device remain sparse. We critically review the existing data, which characterize the risk profile and efficacy of endovascular interventions for intracranial atherosclerotic disease, as well as the available clinical evidence that could be used to select appropriate patients for treatment.
Gateway 球囊-翼型支架系统是美国首个也是目前唯一一个“适应证内”用于治疗症状性颅内狭窄的设备。在最初的单臂研究中,研究人员表明,该系统可用于治疗症状性颅内动脉粥样硬化疾病,具有较高的技术成功率和可接受的围手术期并发症发生率,与其他血管内技术报告的结果相当,甚至更好。接受 Wingspan 装置治疗的患者的中期和长期随访数据仍然很少。我们对现有的数据进行了批判性审查,这些数据描述了血管内介入治疗颅内动脉粥样硬化疾病的风险概况和疗效,以及可用于选择合适患者进行治疗的现有临床证据。